Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Cash from Investing Activities: 2022-2024

Historic Cash from Investing Activities for Addex Therapeutics (ADXN) over the last 1 years, with Dec 2024 value amounting to -$5,320.8 billion.

  • Addex Therapeutics' Cash from Investing Activities fell 83827.03% to -$5,320.8 billion in Q4 2024 from the same period last year, while for Dec 2024 it was $64.7 billion, marking a year-over-year increase of 89768.29%. This contributed to the annual value of $5.3 million for FY2024, which is 69410.78% up from last year.
  • As of Q4 2024, Addex Therapeutics' Cash from Investing Activities stood at -$5,320.8 billion, which was down 198.90% from $5,379.9 billion recorded in Q3 2024.
  • In the past 5 years, Addex Therapeutics' Cash from Investing Activities ranged from a high of $5,379.9 billion in Q3 2024 and a low of -$5,320.8 billion during Q4 2024.
  • Its 3-year average for Cash from Investing Activities is $8.5 billion, with a median of -$2,669 in 2023.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first surged by 68,023,512,464.92% in 2023, then crashed by 83,827.03% in 2024.
  • Over the past 3 years, Addex Therapeutics' Cash from Investing Activities (Quarterly) stood at -$9.34 in 2022, then surged by 68,023,512,464.92% to $6.4 billion in 2023, then plummeted by 83,827.03% to -$5,320.8 billion in 2024.
  • Its Cash from Investing Activities was -$5,320.8 billion in Q4 2024, compared to $5,379.9 billion in Q3 2024 and $6.4 billion in Q4 2023.